To understand why a chemical modification on a stretch of DNA commands such attention, one has to start with the biology. The MGMT gene encodes O6-methylguanine-DNA methyltransferase, a suicide enzyme that patrols the genome and directly reverses a specific type of alkylation damage: the addition of methyl or larger alkyl groups to the O6 position of guanine. This is precisely the lesion created by temozolomide, the backbone chemotherapy drug for glioblastoma, and by nitrosoureas such as lomustine. When the drug damages DNA at O6-methylguanine, MGMT removes the offending adduct and, in the process, consumes itself, sacrificing one protein molecule per repair event. Tumor cells with abundant MGMT are therefore armored against alkylating chemotherapy; they simply undo the damage faster than the drug can inflict it.

The elegant twist is that the MGMT promoter contains a CpG island, a GC-rich region where cytosines can be methylated. When methylation spreads across this promoter, the gene is transcriptionally silenced, and the repair enzyme disappears. Tumor cells lacking MGMT cannot correct O6-alkylguanine lesions, so the damage accumulates, triggers futile cycles of mismatch repair, and culminates in cell death. Methylation of the promoter, in other words, converts temozolomide from a modestly effective drug into a genuinely lethal one for the tumor. The landmark 2005 study by Hegi and colleagues in the New England Journal of Medicine demonstrated this in patients: glioblastoma patients with a methylated MGMT promoter derived clear survival benefit from adding temozolomide to radiotherapy, while those with an unmethylated promoter benefited far less. That finding transformed MGMT promoter methylation from a laboratory curiosity into a decision-making tool used in clinics worldwide.

The predictive logic has since been extended and refined. In elderly patients, where the toxicity of combined chemoradiation is a serious concern, trials such as NOA-08 and the Nordic trial used MGMT methylation to justify temozolomide alone or hypofractionated radiotherapy as alternatives to standard treatment. A 2024 reanalysis of the CE.6 and pooled Nordic/NOA-08 trials by Hegi and colleagues went further, concluding that glioblastomas with a truly unmethylated MGMT promoter derive no benefit from temozolomide at all, a finding that strengthens the case for omitting the drug in that population. Conversely, the CeTeG/NOA-09 trial showed that patients with methylated tumors could safely intensify therapy with a lomustine-temozolomide combination, improving survival. Methylation status also predicts pseudoprogression, the inflammatory radiographic mimic of tumor growth that appears after chemoradiation, and it is now embedded in the RANO 2.0 response assessment criteria that govern how treatment response is judged in trials and clinics.

Yet the review is equally clear that measuring this biomarker is far harder than interpreting it. There is no single gold-standard assay. Methylation-specific PCR, the quantitative real-time version validated by Vlassenbroeck and colleagues, offers speed and sensitivity but interrogates only a handful of CpG sites. Pyrosequencing provides quantitative methylation percentages across selected CpG positions and has met clinical and analytical performance criteria in prospective multicenter validation, but different laboratories target different CpG sites and apply different cutoffs. Genome-wide methylation arrays, now routine in DNA methylation-based tumor classification, can derive MGMT status through algorithms such as MGMT-STP27, allowing methylation calls to be extracted from data already generated for classification purposes. Each method answers a slightly different question about a heterogeneous chemical landscape, and the results do not always agree.

The consequences of this methodological fragmentation are real. An international survey published in Neuro-Oncology Practice asked practitioners whether they truly knew who had a methylated glioma, and the answers revealed widespread uncertainty about assay choice and interpretation. A comprehensive Cochrane-based meta-analysis by Brandner and colleagues confirmed that MGMT testing predicts overall survival in temozolomide-treated glioblastoma patients, but also highlighted how much the accuracy of that prediction depends on the assay used. Tumors with intermediate, so-called gray-zone methylation sit in an interpretive no-man’s-land: partially methylated, they confound binary methylated-or-unmethylated reporting, yet clinical decisions demand a yes-or-no answer. Studies have shown that the number of methylated CpG sites correlates linearly with outcome, suggesting that the dichotomization itself discards meaningful information.

Pre-analytical and biological pitfalls compound the technical ones. Bisulfite conversion, the chemical step underlying most methylation assays, degrades DNA and can lose material unevenly. Intratumoral heterogeneity means a sample from one region of a glioblastoma may not represent the whole. Rare genetic events can masquerade as methylation results: the review’s own authors have reported that homozygous deletion of the MGMT gene, which removes the DNA template entirely, creates a potential pitfall for methylation testing, and other work has described genomic rearrangements of MGMT that contribute to chemotherapy resistance independently of promoter methylation. MGMT expression can also be induced by treatment itself, as xenograft studies demonstrated, meaning a tumor’s initial methylation status may not capture its evolving resistance biology. Immunohistochemistry for the MGMT protein, once hoped to be a simpler surrogate, has been hampered by observer variability and lack of association with survival in validation studies.

The biomarker’s reach now extends well beyond glioblastoma. In IDH-mutant astrocytomas, MGMT methylation contributes to prognostic stratification, although analyses from the CATNON trial program found that the MGMT-STP27 algorithm’s methylation call was not predictive of temozolomide benefit in IDH-mutant anaplastic astrocytomas, complicating the simple predictive story. In 1p/19q-codeleted oligodendrogliomas and in 1p/19q-intact lower-grade gliomas, methylation status associates with survival after alkylating chemotherapy. Emerging data address rare entities such as H3 G34-mutant diffuse hemispheric glioma. A uniform analysis of more than 15,000 nervous system tumors from the Mayo group, cited in the review, is helping map where methylation matters diagnostically and where it is merely passenger biology. The picture that emerges is of a biomarker whose meaning shifts with tumor type, IDH status, and treatment context, demanding increasingly sophisticated interpretation.

Looking forward, the review identifies several converging trajectories. Nanopore sequencing, which reads native DNA and detects methylation directly without bisulfite conversion, has been shown by Halldorsson and colleagues to deliver accurate and comprehensive evaluation of MGMT promoter methylation, potentially eliminating an entire class of pre-analytical artifacts. Droplet digital PCR assays for MGMT methylation are undergoing analytical and clinical validation as more quantitative and robust alternatives to conventional qPCR. Artificial intelligence applied to multiparametric MRI is being trained to predict methylation status noninvasively, using radiomic features from intratumoral and peritumoral imaging, with machine learning models combining imaging and clinical data to distinguish pseudoprogression from true progression. CRISPR-based epigenetic tools, including CRISPRoff and dCas9-mediated silencing, are being used experimentally to manipulate MGMT expression and sensitize tumors to temozolomide, hinting at a future where the biomarker becomes a therapeutic target rather than merely a prognostic readout.

What makes this review resonate beyond the specialist literature is the tension it exposes at the heart of precision oncology. MGMT promoter methylation is simultaneously a triumph, a two-decade-old biomarker that still determines whether thousands of patients receive a drug that can only help them, and a cautionary tale, a test with no standardized method, contested cutoffs, and a gray zone that defies the binary answers clinicians need. Platform trials such as GBM AGILE and the Individualized Screening Trial of Innovative Glioblastoma Therapy now use methylation status to stratify patients toward experimental arms, raising the stakes of every ambiguous result. The Mayo Clinic authors’ verdict is measured but firm: the technical and interpretative challenges are ongoing, yet the biomarker’s clinical value is not in doubt. The task ahead is not to replace MGMT methylation but to tame it, with harmonized assays, quantitative reporting, and technologies that measure the epigenome as it actually exists rather than as a convenient yes-or-no label.

Subject of Research: MGMT promoter methylation as a molecular biomarker for diagnosis and treatment decisions in central nervous system tumors

Article Title: MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions

Article References: Do, T. J., Shafqat, S., Kizilbash, S. H., & Ida, C. M. (2026). MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions. Journal of Neuro-Oncology, 180(1), Article 16. https://doi.org/10.1007/s11060-026-05821-y

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05821-y

Keywords: MGMT promoter methylation, glioblastoma, temozolomide, DNA methylation, neuro-oncology, biomarker testing, pyrosequencing, methylation-specific PCR, nanopore sequencing, epigenetics, IDH-mutant glioma, pseudoprogression

Sacituzumab govitecan is a targeted therapeutic that couples an antibody directed against Trop-2, a cell-surface protein abundantly expressed in many epithelial cancers, to SN-38, the active metabolite of the widely used chemotherapy drug irinotecan. Once the antibody binds Trop-2 on the tumor cell surface and the complex is internalized, the cleavable linker releases SN-38, which poisons topoisomerase I and stalls DNA replication. In the pivotal ASCENT trial, the drug nearly doubled median progression-free survival compared with single-agent chemotherapy in metastatic triple-negative breast cancer, and it subsequently earned regulatory approval as a standard of care in the later-line setting. Those landmark results, however, were generated in patient populations in which metaplastic cancers were either absent or represented only a vanishingly small subset, leaving clinicians with little more than scattered case reports to inform decisions for this especially aggressive group.

The Massachusetts General team, led by Shivahamy Maheswaran and Arielle J. Medford with senior author Aditya Bardia, addressed that gap by interrogating their institutional database of patients with metastatic triple-negative breast cancer treated between 2000 and 2025. They identified seventeen patients with metaplastic disease who had received sacituzumab govitecan and compared their outcomes with 133 patients who had non-metaplastic triple-negative tumors treated at the same center over the same quarter-century. Metaplastic breast cancer is defined histologically by the presence of squamous, spindle-cell, or other mesenchymal-like differentiation within an otherwise adenocarcinoma framework, a feature thought to reflect profound lineage plasticity and to contribute to chemotherapy resistance. Prior studies have repeatedly documented poorer responses to neoadjuvant chemotherapy and shorter survival in metaplastic cases, making the question of whether antibody-drug conjugates can overcome this resistance clinically urgent.

The headline result was a numerically shorter median progression-free survival on sacituzumab govitecan for patients with metaplastic disease: 2.6 months versus 6.8 months for non-metaplastic triple-negative breast cancer. Because of the small number of metaplastic cases, this difference did not reach conventional statistical significance, with a p-value of 0.16, and the authors are careful to frame it as a signal rather than a definitive conclusion. Multivariable Cox regression was used to adjust for potential confounders when assessing the association between metaplastic histology and both progression-free and overall survival. Most patients with metaplastic tumors showed limited benefit from the drug as monotherapy, a pattern consistent with the subtype’s documented resistance to cytotoxic and targeted agents alike. For a cancer in which every additional month of disease control matters, the roughly four-month gap in median progression-free survival, even if imprecisely estimated, represents a clinically meaningful shortfall that clinicians must weigh when sequencing therapy.

Yet the study was not uniformly pessimistic. Two patients with metaplastic disease who received sacituzumab govitecan in combination with talazoparib, an oral PARP inhibitor, experienced unusually prolonged progression-free survival. This observation carries mechanistic logic. PARP inhibitors exploit a synthetic-lethal vulnerability in tumors with defective homologous recombination DNA repair, typically driven by germline or somatic BRCA1 or BRCA2 mutations, while topoisomerase I poisoning by SN-38 generates replication-associated DNA lesions that PARP-mediated repair would normally resolve. Preclinical work has shown that combining an anti-Trop-2 antibody-drug conjugate with PARP inhibition can be effective even in BRCA-wild-type triple-negative models, and early-phase studies such as SEASTAR, which paired the PARP inhibitor rucaparib with sacituzumab govitecan, have explored this strategy across tumor types. A sequential topoisomerase I and PARP inhibitor approach has also been proposed as a rational therapeutic rhythm in breast cancer. The two long-responding patients in this cohort, though anecdotal, provide a concrete clinical anchor for that hypothesis in metaplastic disease.

Beyond treatment response, the investigators undertook a systematic annotation of genomic and pathology data from all fifty-eight patients with metaplastic breast cancer in their database, regardless of treatment, to characterize how many harbored actionable biomarkers. The results were striking. Thirty-four of fifty-six patients with evaluable HER2 immunohistochemistry qualified as HER2-low, defined as staining of 1+ or 2+ without amplification, a status that renders tumors eligible for trastuzumab deruxtecan, a different antibody-drug conjugate that demonstrated survival benefit in HER2-low metastatic breast cancer. Eight of forty-five patients tested carried germline BRCA1 or BRCA2 mutations, opening the door to PARP inhibitor monotherapy or platinum-based regimens. Nine of thirty patients with sequencing data had somatic PIK3CA mutations, potentially qualifying them for PI3K-alpha inhibitor therapy. In aggregate, a substantial majority of the metaplastic cohort carried at least one biomarker linked to an approved or investigational targeted therapy, a finding that argues strongly for comprehensive molecular profiling at the time of metastatic diagnosis.

The authors also examined how patients with metaplastic tumors fared on matched targeted therapies when such treatments were actually delivered, and the answer was heterogeneity: progression-free survival on matched therapy varied considerably from patient to patient. This variability echoes a broader theme in precision oncology, namely that the presence of an actionable alteration does not guarantee sensitivity to the corresponding drug, particularly in tumors as genomically chaotic as metaplastic carcinomas, which often combine epithelial and mesenchymal features, high mutational burden, and complex copy-number landscapes. Prior genomic characterizations of paired metaplastic samples have documented marked tumor evolution under therapeutic pressure, suggesting that clonal selection may rapidly erode the relevance of a biomarker identified in an earlier biopsy. Real-time, repeated profiling of plasma and tissue may therefore be necessary to keep treatment aligned with the evolving genome.

The study’s limitations are inherent to its design and to the rarity of the disease it examines. It is a single-institution retrospective cohort, spanning a period during which sequencing practices, biomarker definitions, and treatment standards all changed substantially. Seventeen treated metaplastic patients is a small number by any statistical standard, and the authors themselves note that the absence of a significant p-value should not be mistaken for evidence of equivalence. Not every patient had every biomarker assessed, which explains the differing denominators across the HER2-low, germline BRCA, and PIK3CA analyses. Selection bias in who received sacituzumab govitecan, and in who underwent genomic testing, cannot be excluded. These constraints do not undermine the central observations, but they do mean that the estimates of survival and biomarker frequency carry wide uncertainty, and they underscore why no single center can realistically resolve the clinical questions surrounding a disease this uncommon.

That last point is the study’s clearest message to the field. The authors argue that multi-institutional collaboration and deliberately inclusive trial design are essential to optimize treatment for metaplastic breast cancer, and the structure of their own evidence base illustrates why. Case reports and small case series, which until now constituted essentially the entire literature on antibody-drug conjugates in this subtype, cannot distinguish signal from noise. Registry-based efforts, international consortia, and trial protocols that either stratify for or explicitly enroll metaplastic histology are the only realistic path to generating adequately powered evidence. In the meantime, the practical takeaways for clinicians are concrete: comprehensive biomarker testing, including HER2-low assessment by immunohistochemistry, germline BRCA testing, and broad next-generation sequencing of tissue or plasma, should be standard for every patient with metastatic metaplastic triple-negative breast cancer, and combination strategies pairing sacituzumab govitecan with DNA-damage-response agents such as PARP inhibitors deserve prospective evaluation rather than remaining an anecdotal rescue option.

For patients, the study tempers expectations without closing doors. Sacituzumab govitecan remains a rational choice in later-line metastatic triple-negative breast cancer, but the data suggest that metaplastic histology should prompt heightened vigilance for early progression and a low threshold for pursuing molecular profiling and clinical trial enrollment. The identification of targetable alterations in the majority of characterized tumors reframes this rare cancer not as an untreatable outlier but as a genomically diverse disease in which the right drug for the right alteration, delivered at the right time, may still shift the trajectory. Turning that possibility into reliable outcomes will require exactly what the authors call for: shared data, collaborative trials, and a willingness to design studies around the rarest and most resistant corners of breast cancer biology.

Subject of Research: Response of metastatic metaplastic triple-negative breast cancer to the antibody-drug conjugate sacituzumab govitecan and the frequency of actionable genomic biomarkers

Article Title: Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability

Article References: Maheswaran, S., Dedeoglu, A. S., Niemierko, A., Abelman, R. O., Jimenez, R., Rieur, O., Hutchinson, J., Vidula, N., Spring, L. M., Ellisen, L. W., Isakoff, S. J., Wander, S. A., Bardia, A., & Medford, A. J. (2026). Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability. Breast Cancer Research and Treatment, 219(3), Article 26. https://doi.org/10.1007/s10549-026-08079-0

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08079-0

Keywords: metaplastic breast cancer, triple-negative breast cancer, sacituzumab govitecan, antibody-drug conjugate, HER2-low, BRCA mutations, PIK3CA, PARP inhibitor, talazoparib, biomarker testing, progression-free survival, precision oncology

The study was conducted between September 19 and November 4, 2024, using a stratified random sampling method designed to capture the diversity of Chinese clinical practice. Respondents included 48 surgeons, 48 oncologists, and 24 interventionalists or radiotherapists drawn from tier 1, 2, and 3 cities, including Beijing, Shanghai, Guangzhou, Shenzhen, Wuhan, Chengdu, Xiamen, Fuzhou, and Wuxi. All participating hospitals were ranked secondary A or higher within China’s three-tier hospital classification system and each saw more than 100 patients with biliary tract cancer per year. The physicians averaged 16 years of experience in managing advanced disease, and two-thirds held the title of associate chief physician or above.

The clinical picture that emerged is sobering. Physicians estimated that 58.2 percent of patients with advanced biliary tract cancer are initially deemed to have unresectable tumors, meaning surgery, the only potentially curative option, is off the table from the start. Approximately half of patients present with locally advanced disease, while 44.4 percent have metastatic disease. Most respondents, 85.8 percent, indicated that between 30 and 80 percent of their patients have unresectable or metastatic disease at diagnosis, a figure consistent with the disease’s insidious onset. Because early-stage biliary tract cancer produces few or no symptoms, most patients are diagnosed only after the tumor has progressed beyond the reach of the scalpel.

The survey also documented a shift in the disease’s anatomical distribution. Respondents reported that intrahepatic cholangiocarcinoma, which arises within the liver’s bile ducts, was the most common subtype they encountered, accounting for an estimated 39.2 percent of cases, followed by extrahepatic cholangiocarcinoma at 34.6 percent and gallbladder cancer at 26.2 percent. That ordering differs from epidemiological data collected in China between 2008 and 2012, when gallbladder cancer was the most frequently diagnosed subtype. The authors suggest this shift may reflect changing risk factors, including hepatitis B and C infection, obesity, and diabetes, which have driven a rise in intrahepatic tumors.

On the treatment front, the survey found that physicians estimated 77.3 percent of patients with advanced disease receive first-line therapy, while 22.8 percent receive no antitumor treatment at all. Among those who are treated, immunotherapy combined with chemotherapy was the most commonly used first-line modality, selected by 34.2 percent of physicians, followed by chemotherapy alone at 15.8 percent and local-regional combination therapies at 10.8 percent. Yet guidelines from both China and the National Comprehensive Cancer Network recommend immunotherapy plus chemotherapy as the preferred first-line approach, based on phase 3 trials showing that adding durvalumab or pembrolizumab to gemcitabine and cisplatin improves survival compared with chemotherapy alone. Only about a third of surveyed physicians reported following that standard, exposing a substantial implementation gap.

The specific regimens physicians chose reveal further nuances. Gemcitabine plus cisplatin combined with immunotherapy was the most frequently used immunochemotherapy combination, cited by 52.4 percent of respondents, followed by gemcitabine plus oxaliplatin plus immunotherapy at 31.1 percent. The most commonly paired immunotherapy drugs were durvalumab, sintilimab, tislelizumab, and pembrolizumab. Notably, the survey found relatively high use of sintilimab and tislelizumab despite limited evidence supporting their use in biliary tract cancer, suggesting that real-world practice in China deviates from the evidence base in ways that may reflect drug availability and cost rather than clinical trial data. Targeted therapies, such as FGFR and HER2 inhibitors, remained rare in the first-line setting, used in combination with immunotherapy by only 4.2 percent of physicians.

Geography and economics clearly shape treatment decisions. Physicians in tier 1 and tier 2 cities were significantly more likely than those in tier 3 cities to cite patient baseline status and economic considerations as key factors in choosing an immunochemotherapy regimen, differences the authors attribute to uneven distribution of healthcare resources, hospital capacity, and access to novel therapies. The reasons physicians gave for choosing chemotherapy alone included disease characteristics, patient baseline status, economic considerations, and the evidence level of the regimen. The relatively poor tolerability of gemcitabine plus cisplatin, which is associated with nephrotoxicity, nausea, vomiting, and anorexia, may also explain why some clinicians opt for alternative chemotherapy backbones such as GEMOX.

The picture darkens further after first-line treatment fails. Physicians estimated that only 43.8 percent of patients proceed to subsequent therapy after disease progression, with the overwhelming majority of physicians, 94.2 percent, citing the patient’s inability to tolerate existing regimens as the main barrier. Economic constraints and medications falling outside insurance coverage were cited by 65 percent, and patient transfers to other hospitals by 63.3 percent. Among those who do continue treatment, immunotherapy plus chemotherapy was the most common subsequent modality, followed by chemotherapy alone and immunotherapy plus an anti-angiogenic agent. Existing second-line options offer only modest efficacy, underscoring what the survey’s respondents identified as the field’s most pressing unmet needs: a limited selection of treatment regimens, cited by 46.7 percent, and financial barriers to care, cited by 40 percent.

One of the most intriguing findings concerns conversion and downstaging therapy, an approach in which systemic treatment is used to shrink initially unresectable tumors enough to make surgery possible. Roughly 90 percent of surveyed physicians reported experience with this strategy, and most considered patients with technically resectable intrahepatic metastases, large tumors, or vascular invasion to be suitable candidates. Immunotherapy plus chemotherapy and triplet therapy combining immunotherapy, chemotherapy, and an anti-angiogenic agent were viewed as the most credible conversion regimens. However, most physicians estimated the success rate of conversion therapy at below 40 percent, and the authors caution that phase 3 trials are still needed to validate the efficacy and safety of this increasingly popular approach.

Biomarker testing emerged as another critical bottleneck in the pathway to precision medicine. Although 51.7 percent of physicians expressed high willingness to test patients for actionable gene mutations such as IDH1, HER2, and FGFR2, and for immune-related markers including PD-L1 and tumor mutational burden, only 63.3 percent reported that 20 to 50 percent of their patients were actually tested. High testing cost was cited by 93.3 percent of physicians as the main obstacle, and nearly all noted that the positive detection rate for both immune-related markers and actionable mutations was below 20 percent. Even among patients who tested positive, fewer than half, 41.5 percent, went on to receive biomarker-guided medication, primarily because of economic considerations, poor tolerability, and limited guideline support. Overall physician satisfaction with current treatment and management of advanced biliary tract cancer ranged from 6.1 to 7.5 out of 10, with the lowest scores assigned to overall efficacy and drug accessibility. The authors hope their findings will inform future standardization of care in China, where the incidence and mortality of this challenging cancer continue to rise.

Subject of Research: Treatment patterns and physician decision-making for advanced biliary tract cancer in China

Article Title: Patient Characteristics and Treatment Patterns of Advanced Biliary Tract Cancer (BTC): A Chinese Physician Survey

Article References: Qiu, H., Liu, Q., Wang, Z., Chen, W., Tang, W., & Hao, C. (2026). Patient Characteristics and Treatment Patterns of Advanced Biliary Tract Cancer (BTC): A Chinese Physician Survey. Advances in Therapy. https://doi.org/10.1007/s12325-026-03732-y

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03732-y

Keywords: biliary tract cancer, cholangiocarcinoma, immunotherapy, chemotherapy, China, physician survey, biomarker testing, conversion therapy, gemcitabine, cisplatin, healthcare access, treatment guidelines

The stakes of this testing gap are considerable. ER-positive, HER2-negative disease accounts for roughly 70 percent of all breast cancer cases and, after relapse, is responsible for most breast cancer deaths. Endocrine therapies that disrupt estrogen receptor signaling remain the backbone of treatment, often combined with CDK4/6 inhibitors as first-line therapy. Yet most patients eventually progress, typically within two to three years, and mutations in the ligand-binding domain of ESR1 are a major mechanism by which tumors escape estrogen deprivation. These mutations are rare at initial metastatic diagnosis, detected in fewer than 5 percent of patients before first-line therapy, but they emerge over time under the selective pressure of aromatase inhibitors and other endocrine treatments, reaching appreciable prevalence in patients with recurrent or endocrine-resistant disease.

The clinical landscape shifted decisively in 2023 when the FDA approved elacestrant, an oral selective estrogen receptor degrader, for patients with ESR1-mutated, ER-positive/HER2-negative advanced disease that had progressed after at least one line of endocrine therapy, alongside the Guardant360 CDx assay as a companion diagnostic. A second oral SERD, imlunestrant, followed in 2025. More provocatively, the phase 3 SERENA-6 trial demonstrated that switching patients to camizestrant upon detection of an emergent ESR1 mutation during first-line treatment, while continuing the CDK4/6 inhibitor, significantly improved progression-free survival compared with continued aromatase inhibitor therapy, with a hazard ratio of 0.44. The earlier PADA-1 trial had already shown a similar benefit for mutation-guided switching to fulvestrant. Together, these results argue that serial monitoring for ESR1 mutations before radiologic progression could fundamentally change how first-line therapy is managed.

Against that backdrop, the new study set out to quantify how often ESR1 testing actually occurs, when mutations appear during first-line treatment, and which patients get tested. Among the 7,772 patients who initiated first-line therapy, only 222, or 3 percent, had an ESR1 test result reported in the 90 days before treatment began, and just 1,355, or 17 percent, were tested at any point during first-line therapy. Even among patients who moved on to a second line of treatment, fewer than a quarter had been tested on or before the start of that line. Testing rates did climb over the study period, rising from 11 percent of patients diagnosed in 2018 and 2019 to 19 percent in 2020 and 2021 and 22 percent in 2022 through 2024, but the authors emphasize that the vast majority of tumors were never interrogated for this actionable biomarker.

The mechanics of testing also revealed a heavy reliance on tissue rather than blood. Of the 1,595 tests performed during first-line therapy, 60 percent used tissue specimens while 40 percent used liquid biopsies that detect circulating tumor DNA. Nearly all tests, 96 percent, were next-generation sequencing assays, with Foundation Medicine and Guardant serving as the most common testing providers. The median turnaround time from specimen collection to result reporting was 28 days, although for a quarter of tests more than 12 weeks elapsed before results were available, a lag that matters when treatment decisions may hinge on timely mutation detection. Guideline recommendations from ASCO updated in 2023 favor ctDNA-based testing at progression precisely because it enables less invasive, serial monitoring.

Perhaps the most clinically consequential finding concerns the timing of mutation emergence. Using the date each specimen was collected, rather than the date results were reported, the researchers calculated that ESR1 test positivity was 6.7 percent among specimens provided at baseline, rising to 23 percent for specimens collected 9 to 12 months into first-line therapy, 38 percent at 15 to 18 months, and 40 percent at 18 to 24 months. Critically, mutations were detected in specimens collected across every time interval, demonstrating that ESR1 mutations can emerge at essentially any point during treatment rather than clustering predictably around a single window. This dynamic, rolling pattern of emergence echoes kinetics data from PADA-1, where cumulative incidence approached 40 percent before or at progression but instantaneous detection rates varied unevenly across the treatment course.

The spectrum of mutations observed reinforced known biology. In the secondary clinico-genomic cohort, the most common variants were D538G, found in 43 percent of mutated tumors, followed by Y537S at 30 percent and E380Q at 23 percent, all canonical ligand-binding domain alterations. Multiple ESR1 variants coexisted in 19 percent of mutated tumors. Among patients whose tumors acquired ESR1 mutations during first-line therapy, co-mutations were frequent: PIK3CA alterations appeared in 38 percent of those tested, BRCA1 or BRCA2 alterations in 10 percent, AKT1 in 4 percent, and PTEN in under 3 percent, underscoring that ESR1 is one of several resistance mechanisms at work in these tumors.

Who gets tested also proved informative. Patients tested during first-line therapy were demographically similar to those not tested, with comparable ages, sexes, races, and rates of liver metastases, though tested patients were somewhat more likely to receive care in community oncology practices, a pattern the authors caution may reflect documentation differences rather than true practice variation. Prior endocrine therapy exposure emerged as a meaningful correlate of baseline positivity: among patients with recurrent disease previously treated with aromatase inhibitor in the early-stage setting, 22 percent of those tested before first-line therapy harbored ESR1 mutations, and positivity rose to 21 percent among patients with two or more years of prior endocrine therapy, compared with 10 percent among those with less than a year of exposure.

The study’s limitations temper some interpretations. Because testing was not standard of care for much of the period studied, tested patients cannot be assumed to represent the broader population, and positivity rates may be overestimates if testing was prompted by unmeasured signals of disease worsening. Most patients were never tested, and those who were typically provided only a single specimen. The small number of specimens in some time intervals limited the precision of positivity estimates. Nonetheless, the consistency of the findings with randomized trial kinetics data lends credibility to the central conclusion: ESR1 mutations are a dynamic, time-dependent feature of first-line treatment, and one-time or infrequent testing is structurally incapable of catching them reliably. In SERENA-6, a single test detected only half of emergent mutations, while two to five serial tests detected up to 90 percent.

The authors argue that the observed testing shortfall represents a concrete opportunity. With mutation-guided switching now supported by randomized evidence linking early detection to prolonged progression-free survival, delayed deterioration in patient-reported outcomes, and better maintenance of health-related quality of life, frequent ctDNA-based surveillance during first-line therapy could allow oncologists to intercept endocrine resistance before scans confirm progression. As oral SERDs multiply and guidelines increasingly endorse molecular monitoring, this real-world dataset serves as both a benchmark and a warning: the science of anticipatory, adaptive oncology is ready, but routine practice has not yet caught up with it.

Subject of Research: Real-world ESR1 mutation testing patterns and emergence during first-line treatment of ER-positive/HER2-negative metastatic breast cancer in the United States

Article Title: Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018–2024

Article References: Meisel, J., Pham, T., Chen, C., Kris, A., & Roose, J. (2026). Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018–2024. Breast Cancer Research and Treatment, 219(2), Article 8. https://doi.org/10.1007/s10549-026-08060-x

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08060-x

Keywords: ESR1 mutation, metastatic breast cancer, endocrine therapy resistance, liquid biopsy, circulating tumor DNA, SERD, elacestrant, camizestrant, SERENA-6, next-generation sequencing, CDK4/6 inhibitor, biomarker testing